KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Assets (2016 - 2025)

Historic Current Assets for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.

  • Ionis Pharmaceuticals' Current Assets fell 718.01% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 718.01%. This contributed to the annual value of $2.6 billion for FY2024, which is 81.62% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Current Assets stood at $2.5 billion for Q3 2025, which was down 718.01% from $2.6 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Current Assets ranged from a high of $2.7 billion in Q3 2024 and a low of $2.0 billion during Q1 2021
  • For the 5-year period, Ionis Pharmaceuticals' Current Assets averaged around $2.4 billion, with its median value being $2.4 billion (2024).
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 2222.9% in 2021, then surged by 2009.75% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Current Assets (Quarter) stood at $2.3 billion in 2021, then decreased by 6.07% to $2.2 billion in 2022, then grew by 19.94% to $2.6 billion in 2023, then dropped by 0.82% to $2.6 billion in 2024, then fell by 3.87% to $2.5 billion in 2025.
  • Its last three reported values are $2.5 billion in Q3 2025, $2.6 billion for Q2 2025, and $2.4 billion during Q1 2025.